ArticleIn vivo (Athens, Greece)
Prognostic Role of Inflammatory Blood Cell Ratios in Glioblastoma Patients: Insights from a Single-institution Study.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimGlioblastoma multiforme (GBM) is the most common and aggressive primary malignant brain tumor, with a poor prognosis despite standardized multimodal treatment. Recent research has explored the prognostic value of systemic inflammatory markers, which could provide accessible and cost-effective indicators of patient outcomes. PATIENTS AND
methodsThis retrospective single-center study analyzed patients with GBM treated between 2014 and 2024. Eligible patients underwent radiotherapy with concurrent and adjuvant temozolomide. Hematological parameters, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), and systemic inflammatory response index (SIRI), were assessed for prognostic significance. Overall survival (OS) was analyzed using Kaplan-Meier curves and Cox regression models.
resultsA total of 74 newly diagnosed patients with GBM were included, with a median follow-up of 18 months. ROC curve analysis identified significant cutoff values for NLR, MLR, SII, and SIRI, which were associated with OS. Patients with elevated inflammatory markers had significantly worse OS. Median OS was significantly shorter in patients with elevated NLR (14 months
conclusionThis study confirms the prognostic relevance of systemic inflammatory markers, particularly NLR, MLR, SII, and SIRI, in patients with GBM. These easily obtainable parameters could complement molecular profiling in risk stratification and treatment planning, pending validation in prospective studies, and contribute to more personalized patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.